• Login
    View Item 
    •   UNZA Repository Home
    • African Digital Health Library (ADHL) - Zambia
    • Medical Journal of Zambia
    • View Item
    •   UNZA Repository Home
    • African Digital Health Library (ADHL) - Zambia
    • Medical Journal of Zambia
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    A prospective study of agaricus blazei mycelia compound administration in asymptomatic HIV-1 infected patients in Lusaka, Zambia

    Thumbnail
    View/Open
    Journal Article (864.2Kb)
    Date
    2007-01
    Author
    Handema, R.
    Terunuma, H.
    Kasolo, F.
    Type
    Article
    Language
    en
    Metadata
    Show full item record

    Abstract
    Agaricus mycelia compound (ABPC) has been used as a food supplement in Japan for several years. It has been shown to have immune enhancing activities both z.77 vz.fro and z.77 1;z.1;o, leading us to speculate a potential role in the treatment of HIV infection. To determine the value of ABPC as an immune enhancing supplement for HIV-infected individuals, we carried out a prospective randomised clinical study. We recruited 54 HIV-1 infected asymptomatic patients attending a general clinic in Lusaka, Zambia. Informed consent was obtained from all participants after explaining the purpose and details of the study. At recruitment, all patients had blood CD4 counts >200 cells/m61. The study participants were divided into the ABPC group (28 subjects) and placebo group (26 subjects). ABPC or placebo was administered by directly observed therapy methodology. During the 12-month period, 3 and 5 patients died in the ABPC and placebo groups, respectively. During that time, 9 and 5 patients in the ABPC and the placebo groups, respectively, left the study and returned to their villages. After 12 months, the average CD4 counts in the placebo group had significantly decreased (P=0.018), while the numbers were maintained in the ABPC group. This finding suggests that ABPC administration is beneficial for maintaining CD4 counts in patients with HIV infection, thereby delaying the onset of AIDS.
    URI
    http://dspace.unza.zm/handle/123456789/5987
    Citation
    Handema, R., Terunuma, H. and Kasolo, F. (2007). A prospective study of agaricus blazei mycelia compound administration in asymptomatic HIV-1 infected patients in Lusaka, Zambia. Medical Journal of Zambia. 34, (1)
    Sponsorship
    Office of Global AIDS/US Department of State.
    Publisher
    Medical Journal of Zambia.
    Subject
    Agaricus
    Mycelia
    Mycelium
    HIV Infections--Zambia
    Description
    Agaricus mycelia compound (ABPC) has been used as a food supplement in Japan for several years
    Collections
    • Medical Journal of Zambia [187]

    DSpace software copyright © 2002-2016  DuraSpace
    UNZA homepage | UNZA Library | Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of UNZA RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    DSpace software copyright © 2002-2016  DuraSpace
    UNZA homepage | UNZA Library | Contact Us | Send Feedback
    Theme by 
    Atmire NV